ERBB3


Also found in: Wikipedia.

ERBB3

A gene on chromosome 12q13 that encodes a member of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases which binds and is activated by neuregulins and NTAK.

Molecular pathology
ERBB3 amplification and overexpression has been described in multiple cancers, including prostate, bladder and breast.
Mentioned in ?
References in periodicals archive ?
CDX-3379-a differentiated human monoclonal antibody designed to block the activity of ErbB3 (HER3).
CDX-3379 is a human monoclonal antibody that uniquely blocks the activity of ErbB3. ErbB3 is expressed in many cancers, including head and neck squamous cell cancer and is believed to be an important receptor regulating cancer cell growth and survival as well as resistance to targeted therapies.
EGFR (Epidermal growth factor receptor) belongs to the erbB family of closely related receptor tyrosine kinases, which include erbB1 (Also known as EGFR), erbB2 (HER2), erbB3, and erbB4.
Lastly, their data suggests that miR203 may constitute a new prognostic factor in canine oral melanoma, and that miR-205 acts as a tumoral suppressor through targeting the ERBB3 gene in canine and human melanoma cells (NOGUCHI et al., 2013).
The ERBB3 receptor in cancer and cancer gene therapy.
The family of receptors in this group is made up of four homologous receptors: epidermal growth factor receptor (ErbB1/EGFR/HER1), HER2 (HER2/neu), ErbB3 (HER3) and ErbB4 (HER4) (3-5).
Upon further analysis of these fetal muscle cells two new cell surface markers called ERBB3 and NGFR were discovered; this enabled the researchers to precisely isolate muscle cells from human tissue and separate them from various cell types created using human pluripotent stem cells.
Li et al., "An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activation," Cancer Research, vol.
Vorinostat, a HDAC inhibitor via inducing ubiquitination and lysosome degradation, downregulates the expression and signaling of all three receptors EGFR, ErbB2, and ErbB3 together with reversion of EMT in EGFR TKI gefitinib-resistant cells and therefore enhances the antitumor effect of gefitinib in squamous cell carcinoma of head and neck [147].
Owens et al., "Conditional loss of ErbB3 delays mammary gland hyperplasia induced by mutant PIK3CA without affecting mammary tumor latency, gene expression, or signaling," Cancer Research, vol.
Mitsudomi et al., "MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling," Science, vol.